In conclusion, our study revealed CSC-derived exo-SNHG16 promoted cancer progression by activating the TLR7/MyD88/NFκB/c-Myc signaling pathway, which might be an attractive target in glioma clinical treatment. Here, MYD88 is linked to glioma.